What PRP, stem cells, and exosomes actually are
Platelet-rich plasma (PRP) is made by drawing a small amount of a patient's own blood and concentrating the platelets, which contain growth factors. Stem cell products in this category typically refer to cells sourced from bone marrow, adipose tissue, or birth tissue (such as umbilical cord or placental tissue). Exosomes are tiny vesicles released by cells that carry proteins and genetic material and are sometimes marketed as a cell-free alternative to stem cell injections. Each of these categories also includes significant variation in how a product is processed and concentrated, which can affect both its composition and the applicability of any published research to a specific commercial product.
These are distinct biological products with different manufacturing processes, different levels of regulatory oversight, and different bodies of research behind them. Treating them as interchangeable is not accurate.
What the evidence says about PRP
The American Academy of Orthopaedic Surgeons (AAOS) has reviewed PRP for certain musculoskeletal conditions, including knee osteoarthritis and some tendon conditions, and the evidence is mixed: some studies show modest symptom improvement for certain uses, while others show no significant benefit compared with control treatments.
A Cochrane review of PRP injections for certain musculoskeletal conditions similarly found the overall quality of evidence to be low to moderate, with uncertain or inconsistent effects across studies, highlighting the need for more rigorous, standardized research before firm conclusions can be drawn.
What the evidence says about stem cell therapies
Stem cell research for orthopedic and other conditions is an active area of investigation, but most consumer-marketed stem cell products have not gone through the FDA approval process required for drugs and biologics. Clinical trials are ongoing for various applications, but it is important to distinguish between a product that is part of a registered, regulated clinical trial and one that is being sold directly to patients outside of that framework.
What the evidence says about exosomes
Exosome research is even earlier-stage than stem cell research in most applications. Exosome products are generally not FDA-approved for the conditions they are frequently marketed for, and rigorous human clinical trial data supporting specific outcome claims is limited. Much of the available research remains preclinical or in early human studies, often involving laboratory models rather than large, controlled human trials, which is an important distinction when evaluating any marketing claim about exosome therapy.
FDA warnings consumers should know about
- The FDA has issued public consumer warnings stating that stem cell and exosome products are not FDA-approved for most marketed uses, and that some clinics have made unsubstantiated claims about their benefits.
- The FDA has taken enforcement action against clinics offering unapproved stem cell products, and has warned that some products have been linked to serious adverse events, including infections.
- The agency recommends that patients ask whether a product has an FDA-approved Biologics License, or is part of a registered clinical trial, before pursuing treatment.
Why 'natural' or 'your own cells' doesn't mean unregulated or risk-free
Because PRP uses a patient's own blood, and some stem cell products use a patient's own tissue, these treatments are sometimes marketed as inherently safe because they are 'natural.' However, the processing, handling, and injection of any biologic material carries procedural risk, and the fact that a product is autologous (from your own body) does not mean a given use is supported by strong clinical evidence or free of risk.
Why marketing claims and published research can diverge
Regenerative medicine is an area where marketing language sometimes moves faster than the underlying science. Terms like "regenerative," "anti-aging," or "cutting-edge" are not regulated claims and do not indicate that a specific product has strong clinical trial support. When researching any treatment in this category, it is worth distinguishing between a general scientific rationale for why a therapy might work and actual published evidence that it does work for a specific condition.
Patients are encouraged to ask for citations to peer-reviewed research for the specific condition they are considering treatment for, rather than relying on general claims about a treatment category as a whole.
How regulatory status differs across these products
It helps to understand that not everything called a biologic faces the same regulatory path. Some orthopedic uses of a patient's own blood or tissue fall under different FDA frameworks than a manufactured, bioengineered, or donor-derived product intended to be more than minimally manipulated. This is part of why the same general category, regenerative medicine, can include products with very different levels of oversight, and why asking direct questions about a specific product's regulatory status is more useful than asking about the category as a whole.
What a consultation for regenerative options actually involves
A responsible consultation includes a review of the specific condition being considered, a transparent discussion of the current evidence (including its limitations) for that condition, and clarity about which products are and are not FDA-approved. It should also include a conversation about realistic expectations, since no regenerative therapy can be presented as guaranteed to produce a specific outcome.
Questions to ask before considering any regenerative treatment
- Is this specific product FDA-approved, or is it being offered outside of an approved indication or clinical trial?
- What does the published evidence say about this treatment for my specific condition, not just regenerative medicine in general?
- What are the known risks and possible side effects of the procedure itself?
- What happens if the treatment does not produce the improvement I'm hoping for?
Frequently asked questions
Is PRP FDA-approved?
PRP preparation systems (the devices used to process blood) can be FDA-cleared, but this is different from the FDA approving PRP as a treatment for a specific condition. Evidence for PRP's effectiveness varies by condition and is often described as mixed.
Are stem cell treatments FDA-approved?
Most stem cell products marketed directly to consumers are not FDA-approved. The FDA has warned that some clinics market unapproved stem cell products with unsubstantiated claims, and recommends asking whether a product has FDA approval or is part of a registered clinical trial.
Are exosome products FDA-approved?
Generally, no. Exosome products are typically not FDA-approved for the conditions they are marketed for, and human clinical evidence remains limited for most applications.
Does using my own cells make a treatment risk-free?
No. Even autologous treatments, made from your own blood or tissue, involve procedural risks and should be evaluated based on available clinical evidence for your specific condition, not assumed to be risk-free because the material originated in your own body. Injection-related risks, such as infection or discomfort at the injection site, apply regardless of the biological source of the material.
What should I expect from a consultation?
A thorough consultation reviews your specific condition, discusses what the current research does and does not support, clarifies the regulatory status of any product discussed, and avoids promising a specific outcome.
Sources
Treatment requires evaluation by a licensed provider. Eligibility is determined by a physician. Individual results vary. This article is educational and is not medical advice.
